表紙
市場調查報告書

PharmaPoint:慢性阻塞性肺病 (COPD) - 全球治療藥市場預測與分析

Chronic Obstructive Pulmonary Disease: Global Drug Forecast and Market Analysis to 2028

出版商 GlobalData 商品編碼 537176
出版日期 內容資訊 英文 154 Pages
訂單完成後即時交付
價格
PharmaPoint:慢性阻塞性肺病 (COPD) - 全球治療藥市場預測與分析 Chronic Obstructive Pulmonary Disease: Global Drug Forecast and Market Analysis to 2028
出版日期: 2020年03月30日內容資訊: 英文 154 Pages
簡介

本報告提供全球慢性阻塞性肺病 (COPD) 治療藥市場相關分析,疾病概要和流行病學的背景,患病人數趨勢預測,臨床實驗的進展,已上市/臨床實驗中的主要治療藥,目前市場未滿足需求,主要企業簡介,全球/主要國家的市場趨勢預測等調查評估。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因與病情生理
    • 病因
    • 病理生理學
  • 分類和分期
  • 症狀
  • 氣喘和COPD的併發症
  • 生活品質 (QoL)

第5章 流行病學

  • 疾病的背景情況
  • 風險要素與並存症
  • 全球趨勢成果
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法
    • 患病者總數
    • 已受診患病人數
    • 已受診患病人數:各重症度
  • COPD的流行病學的預測 (總計11年份)
    • COPD的患病者總數
    • COPD的患病人數:各年齡
    • COPD的患病人數:男女
    • COPD的已受診患病人數
    • COPD的已受診患病人數:各年齡
    • COPD的已受診患病人數:男女
    • COPD的已受診患病人數:各重症度
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第6章 疾病管理

  • 診斷、治療概要
    • 診斷
    • 治療的指南
    • RA的治療用代表性處方藥
    • 臨床診療
  • 美國
  • (5EU)歐洲主要5個國家
  • 日本
  • 澳洲

第7章 競爭評估

  • 概要
  • 長期間作用型β2促效劑
    • Onbrez Breezhaler (indacaterol maleate)
    • Serevent Diskus (salmeterol xinafoate)
    • Striverdi Respimat (olodaterol hydrochloride)
    • Branded formoterol (formoterol fumarate)
    • Brovana (arformoterol tartrate)
  • 長期間作用型毒蕈鹼拮抗劑
    • Spiriva (tiotropium bromide)
    • Tudorza Pressair (aclidinium bromide)
    • Seebri Breezhaler (glycopyrrolate)
    • Incruse Ellipta (umeclidinium bromide)
  • LABA/LAMA固定劑量複方藥物 (FDC)
    • Ultibro Breezhaler (glycopyrrolate + indacaterol maleate)
    • Anoro Ellipta (umeclidinium bromide + vilanterol trifenatate)
    • Duaklir Genuair (aclidinium bromide + formoterol fumarate)
    • Stiolto Respimat (olodaterol hydrochloride + tiotropium bromide)
    • Bevespi Aerosphere (formoterol fumarate + glycopyrrolate)
  • 吸入皮質類固醇/LABA固定劑量複方藥物
    • Advair Diskus (fluticasone propionate + salmeterol xinafoate)
    • Symbicort (budesonide + formoterol fumarate)
    • Breo Ellipta (fluticasone furoate + vilanterol trifenatate)
    • Fostair (beclomethasone dipropionate + formoterol fumarate)
  • Phosphodiesterase (PDE) 抑制劑
    • Daliresp (roflumilast)
    • 其他PDE4抑制劑
  • 短期作用型β2促效劑
    • 概要
  • 短期作用型毒蕈鹼拮抗劑
    • 概要
  • SABA/SAMA固定劑量複方藥物
    • 概要
  • 非標籤藥物治療藥
    • 氣喘治療藥
  • 其他治療等級

第8章 未滿足需求及市場機會分析

  • 概要
  • 對症狀的相關利益者的認識
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 肺活量檢測的進行、訓練的增加
  • 阻止COPD進展的治療藥
  • 特有的表現型的治療藥的生物標記的鑑定
  • 無法獲得呼吸復建服務
  • 戒煙計劃

第9章 開發平台評估

  • 概要
  • 臨床實驗製圖
    • 各級
  • 臨床實驗中有前途的醫藥品
  • LAMA (長時間作用型膽鹼藥)
    • SUN-101 (glycopyrrolate)
    • Revefenacin
  • ICS/LABA/LAMA固定劑量複方藥物 (FDC)
    • CHF-5993 (beclomethasone dipropionate + formoterol fumarate + glycopyrrolate)
    • PT-010 (budesonide + formoterol fumarate + glycopyrrolate)
    • FF/UMEC/VI (fluticasone furoate + umeclidinium bromide + vilanterol trifenatate)
  • IL-5抑制劑
    • Nucala (mepolizumab)
    • Benralizumab
  • 其他臨床實驗中的醫藥品

第10章 現在、未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • AstraZeneca
    • Boehringer Ingelheim
    • Chiesi
    • GlaxoSmithKline
    • Novartis
    • Sunovion

第11章 市場預測

  • 全球市場
    • 患者人口的預測 (mMRC方式/CAT方式)
    • 近幾年主要的動向
    • 市場的推動及阻礙要素
  • 美國
  • (5EU)歐洲主要5個國家
  • 日本
  • 澳洲

第12章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC188PIDR

Chronic obstructive pulmonary disease (COPD) is a common, preventable, incurable, and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation. Long-term exposure to noxious particles or gases such as cigarette smoke and environmental pollution can induce chronic inflammation in the airways, subsequently causing alveolar abnormalities. Pro-inflammatory cytokines, which are secreted from immune cells such as neutrophils, macrophages, and B cells, and CD4+ and CD8+ T lymphocyte infiltration in the lungs, in addition to elastases, can cause destruction and dysfunction within the airways.

This leads to airflow limitation and causes structural abnormalities such as obstructive bronchiolitis and parenchymal destruction (emphysema). In turn, these changes reduce lung elastic recoil and therefore the ability of the airways to remain open during expiration. Symptoms from such changes include dyspnea, wheezing, chronic cough, and sputum over production, which can impact a patient's physical and mental well-being. Although it is currently unknown if the damage to the airways and lungs can be reversed, treatments and lifestyle changes can help slow the progress of the disease.

Key Highlights

  • During the 10-year forecast period, there are 7 pipeline products that are on track to launch, driving a forecast growth in the 7MM from $10.9B in 2018 to $19.3B in 2028, which represents a CAGR of 5.9%.
  • The percentage of drug-treated patients (receiving maintenance treatment only) will rise across the 7MM with an average AGR of 1.19% across all COPD severity grades, reaching over 23 million by 2028.
  • The entry of inhaled corticosteroids/long-acting beta2-agonists/long-acting muscarinic antagonists (ICS/LABA/LAMA) that will include expensive bronchodilators, will continue to take patient share from LABA and LAMA monotherapies, and ICS/LABA dual therapy to simplify treatment management.
  • The entry of anti-eosinophilic biologics from 2024 will boost overall COPD sales despite the small patient population that these therapies will treat. These therapies are only suitable for COPD patients with high levels of eosinophilia, but hold a high price tag.

Key Questions Answered

  • How will the COPD market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2018-2028?
  • What are the most promising late-stage pipeline products for COPD?
  • How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing COPD product options?
  • What are the remaining unmet needs in COPD?
  • What drivers and barriers will affect COPD product sales in the 7MM over the forecast period?

Scope

  • Overview of COPD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline COPD market revenue from 2018-2028. Annual cost of treatment and major pipeline product sales in this forecast period are included.
  • Key topics covered include current COPD treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD product sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global COPD market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global COPD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the COPD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • I dentify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 COPD: Executive Summary

  • 2.1 Sales for COPD by Country, 2018-2028
  • 2.2 GSK continues to dominate the COPD market in 2028
  • 2.3 Despite the Variety of Available Therapies, COPD Remains a Market with High Unmet Need
  • 2.4 Treatments that Reverse the Progression of COPD Remain Elusive
  • 2.5 Pipeline COPD Treatment to Target a Niche Population
  • 2.6 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems
  • 4.3 Symptoms

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for COPD (2018 - 2028)
    • 5.5.1 Total Prevalent Cases of COPD
    • 5.5.2 Sex-Specific Total Prevalent Cases of COPD
    • 5.5.3 Age-Specific Total Prevalent Cases of COPD
    • 5.5.4 Diagnosed Prevalent Cases of COPD
    • 5.5.5 Sex-Specific Diagnosed Prevalent Cases of COPD
    • 5.5.6 Age-Specific Diagnosed Prevalent Cases of COPD
    • 5.5.7 Diagnosed Prevalent Cases of COPD by Severity
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of the Analysis
    • 5.6.3 Strengths of the Analysis

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
  • 6.2 US
  • 6.3 5EU
  • 6.4 Japan

7 Competitive Assessment

  • 7.1 Overview

8 Unmet Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Disease-Modifying Treatments to Reverse the Progression of COPD
  • 8.3 Identification of Biomarkers that Predict Efficacy
  • 8.4 Observance of GOLD Guidelines Among General Practitioners
  • 8.5 Improved Clinical Trial Design
  • 8.6 Earlier Diagnosis and Recognition of Symptoms

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development
    • 9.2.1 IL-4/IL-5 inhibitors
    • 9.2.2 IL-33 inhibitors
    • 9.2.3 PDE inhibitors
    • 9.2.4 CFTR modulators

10 Current and Future Players

11 Market Outlook

12 Appendix

List of Tables

  • Table 1: COPD: Key Metrics in the 7MM
  • Table 2: GOLD Criteria for the Classification of COPD, 2018
  • Table 3: Symptoms of COPD
  • Table 4: Modified mMRC Dyspnea Scale
  • Table 5: Risk Factors and Comorbidities for COPD
  • Table 6: Treatment Guidelines for COPD
  • Table 7: Country Profile - US, 2018
  • Table 8: Region Profile - 5EU, 2018
  • Table 9: Country Profile - Japan, 2018
  • Table 10: Leading Treatments for COPD, 2018
  • Table 11: Comparison of Therapeutic Classes in Development for COPD, 2018-2028
  • Table 12: AstraZeneca's COPD Portfolio Assessment, 2019
  • Table 13: Chiesi's COPD Portfolio Assessment, 2019
  • Table 14: GSK's COPD Portfolio Assessment, 2019
  • Table 15: Novartis' COPD Portfolio Assessment, 2019
  • Table 16: Sunovion's COPD Portfolio Assessment, 2019
  • Table 17: Sunovion's COPD Portfolio Assessment, 2019
  • Table 18: Theravance's COPD Portfolio Assessment, 2019
  • Table 19: COPD Market - Global Drivers and Barriers, 2018-2028
  • Table 20: Key Events Impacting Sales for COPD in the US, 2018-2028
  • Table 21: COPD Market - Drivers and Barriers in the US, 2018-2028
  • Table 22: Key Events Impacting Sales for COPD in the 5EU, 2018-2028
  • Table 23: COPD Market - Drivers and Barriers in the 5EU, 2018-2028
  • Table 24: Key Events Impacting Sales for COPD in the Japan, 2018-2028
  • Table 25: COPD Market - Global Drivers and Barriers in Japan, 2018-2028
  • Table 26: Historical and projected launch dates for COPD across the 7MM, 2018-2028
  • Table 27: Historical and projected expiry dates for COPD across the 7MM, 2018-2028
  • Table 28: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for COPD in 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in COPD for the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of COPD During the Forecast Period
  • Figure 4: Normal Lungs and Lungs with COPD
  • Figure 5: The Pathogenesis of COPD
  • Figure 6: Refined ABCD Assessment Tool for COPD, 2018
  • Figure 7: 7MM, Total Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018
  • Figure 8: 7MM, Diagnosed Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018
  • Figure 9: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of COPD
  • Figure 10: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of COPD
  • Figure 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD by Severity
  • Figure 12: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages ≥35 Years
  • Figure 13: 7MM, Total Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018
  • Figure 14: 7MM, Total Prevalent Cases of COPD by Age, Men and Women, 2018
  • Figure 15: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages ≥35 Years
  • Figure 16: 7MM, Diagnosed Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018
  • Figure 17: 7MM, Diagnosed Prevalent Cases of COPD by Age, Men and Women, 2018
  • Figure 18: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 19: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 20: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 21: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 22: COPD Treatment Algorithm
  • Figure 23: Unmet Needs and Opportunities in COPD
  • Figure 24: Overview of the Development Pipeline in COPD
  • Figure 25: Key Phase II/III Trials for Promising Pipeline Agents
  • Figure 26: Competitive Assessment of Late-Stage Pipeline Agents for COPD
  • Figure 27: Analysis of the Company Portfolio Gap in COPD During the Forecast Period
  • Figure 28: Global Sales for COPD by Country, 2018 and 2028
  • Figure 29: Sales for COPD by Drug Class in the US, 2018 and 2028
  • Figure 30: Sales for COPD by Drug Class in the 5EU, 2018 and 2028
  • Figure 31: Sales for COPD by Drug Class in Japan, 2018 and 2028